{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-071400","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.107186+00:00","generated_at":"2026-06-18T02:09:27.410944+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Prelude Therapeutics enters $75M at-the-market stock offering agreement with Jefferies","bullets":["Company entered Open Market Sale Agreement with Jefferies LLC to sell up to $75M of common stock.","Sales will be made 'at the market' under existing shelf registration statement (File No. 333-261019).","Jefferies receives up to 3.0% commission on gross proceeds; company not obligated to sell any shares.","Agreement terminates upon sale of all shares or earlier termination by either party.","Proceeds intended for general corporate purposes and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-071400","json":"https://secwatch.observer/filing/0001193125-23-071400.json","markdown":"https://secwatch.observer/filing/0001193125-23-071400.md","text":"https://secwatch.observer/filing/0001193125-23-071400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000119312523071400/0001193125-23-071400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000119312523071400/d405925d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T02:09:27.410944+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50a6b177898fdbbd764dac0bae07246400ffa33e","claim":"Prelude Therapeutics Inc entered into Sales Agreement with Jefferies LLC valued at up to $75.0 million (effective 2023-03-15).","evidence_excerpt":"On March 15, 2023, Prelude Therapeutics Incorporated (the “Company”), entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC, as sales agent and/or principal (“Jefferies”), pursuant to which the Company may offer and sell, from time to time to or through Jefferies, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $75.0 million (the “Shares”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312523071400/0001193125-23-071400-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Value","value":"up to $75.0 million"},{"label":"Effective","value":"2023-03-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}